CELENYS is a biotechnology company committed to the creation, development, production and commercialization of a new generation of 3D cell culture scaffolds to bring an innovative dimension to your research.
Celenys – 3D cell culture
Cells grown in 3D cell culture, known in cancer research as spheroids, have a greater resemblance to those in vivo tissues in terms of cellular communication and the development of the extracellular matrix. 3D cell culture also provides a model for cellular migration, differentiation, survival and growth. Additionally, 3D cell culture allows cells to adopt a polarity which is similar to that found in vivo cell polarisation, which does not occur in 2D cell culture where cells can only ever obtain partial polarity. CELENYS’ mission is to develop innovative scaffolds for 3D cell culture to better mimic the cell microenvironment and provide more predictive tools for drug development. BIOMIMESYS, a new generation of hydrogel for 3D cell culture, represents CELENYS’ first product. Celenys has an exciting pipeline of innovative technologies guaranteed to bring a new dimension to life science research over the coming years. Protected by various international patents, the BIOMIMESYS range is currently being extended through the development of specialized BIOMIMESYS with chemically modified scaffolds that have been designed to recreate the different physiologies of specific tissues.
CELENYS is based in Rouen (France). Management Team is composed by Elise Demange, Nicolas Dubois and Agathe Devaux. In 2014 CELENYS raised 1M€ of investment from NCI Gestion and Go Capital. This funding has enabled CELENYS to develop a multidisciplinary team, triple its workforce and move to new laboratories.
More about Celenys : www.celenys.com